Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2011, Article ID 530568, 3 pages
http://dx.doi.org/10.1155/2011/530568
Case Report

Epstein-Barr Virus Reactivation after Infliximab in Rheumatoid Arthritis: A Case Report

1Rheumatology Unit, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41100 Modena, Italy
2Microbiology and Virology Service, Policlinico di Modena, Via del Pozzo 71, 41100 Modena, Italy

Received 2 May 2011; Accepted 30 May 2011

Academic Editors: W. Chierakul, F. Mansour-Ghanaei, and C. G. Meyer

Copyright © 2011 Michele Colaci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Scott and G. H. Kingsley, “Tumor necrosis factor inhibitors for rheumatoid arthritis,” New England Journal of Medicine, vol. 355, no. 7, pp. 704–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. N. F. Crum, E. R. Lederman, and M. R. Wallace, “Infections associated with tumor necrosis factor-α antagonists,” Medicine, vol. 84, no. 5, pp. 291–302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Khraishi, “Comparative overview of safety of the biologics in rheumatoid arthritis,” Journal of Rheumatology, vol. 82, pp. 25–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Boubenider, C. Hiesse, C. Goupy, F. Kriaa, S. Marchand, and B. Charpentier, “Incidence and consequences of post-transplantation lymphoproliferative disorders,” Journal of Nephrology, vol. 10, no. 3, pp. 136–145, 1997. View at Google Scholar · View at Scopus
  5. J. Torre-Cisneros, M. del Castillo, J. J. Castón, M. C. Castro, V. Pérez, and E. Collantes, “Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis,” Rheumatology, vol. 44, no. 9, pp. 1132–1135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Lavagna, M. Bergallo, M. Daperno et al., “Infliximab and the risk of latent viruses reactivation in active Crohn's disease,” Inflammatory Bowel Diseases, vol. 13, no. 7, pp. 896–902, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Balandraud, S. Guis, J. B. Meynard, I. Auger, J. Roudier, and C. Roudier, “Long-term treatment with methotrexate or tumor necrosis factor α inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis,” Arthritis Care and Research, vol. 57, no. 5, pp. 762–767, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. E. McKeown, J. E. Pope, and S. Leaf, “Epstein-Barr virus (EBV) prevalence and the risk of reactivation in patients with inflammatory arthritis using anti-TNF agents and in those who are biologic naive,” Open Rheumatology Journal, vol. 3, pp. 30–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Miceli-Richard, N. Gestermann, C. Amiel et al., “Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies,” Arthritis Research and Therapy, vol. 11, no. 3, article R77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Komatsuda, H. Wakui, T. Nimura, and K. I. Sawada, “Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis,” Modern Rheumatology, vol. 18, no. 3, pp. 315–318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Balandraud, J. Roudier, and C. Roudier, “What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?” Seminars in Arthritis and Rheumatism, vol. 34, no. 5, supplement 1, pp. 31–33, 2005. View at Publisher · View at Google Scholar · View at Scopus